First-in-class Anti-tumor Agent ONC201 Induces Apoptosis in Hematological Malignancies with Wild Type and Mutant p53

Abstract

survivors. Design: Retrospective study from 1992-2011. Setting: Data from Surveillance Epidemiology and End Results-13 registry. Patients: 15,517 FL patients. Main Outcome Measures: 1. Risk of SPM, developing 6 months after the diagnosis of FL, using Standardized Incidence Ratio (SIR) and Absolute Excess Risk (AER). 2. Poisson multivariate regression to study the impact of different variables on the risk of SPM. Results: At 71 months (range 5 -239 months) follow-up, 1766 patients (11.4%) developed SPM with SIR of 1.23 (95% CI 1.18-1.29; p<0.01) and AER of 33.13 per 10,000 population. Significantly increased risk was noted for Hodgkin lymphoma (SIR 5.85; 95% CI 3.62-8.94), NHL (excluding FL recurrence) (SIR 3.69; 95% CI 3.22-4.2) and acute myeloid leukemia (SIR 4.88; 95% CI 3.65-6.38), in addition to various solid malignancies. In Poisson multivariate regression analysis, older age at diagnosis (odds ratio, OR 1.03; 95% CI 1.02-1.04, p<0.01) and men (OR 1.59; 95% CI 1.43-1.78, p<0.01) predicted a higher risk of SPM. Conversely, the rate of SPM has declined in recent years (OR 0.98; 95% CI 0.97-0.99; p<0.01). Conclusion: Patients with FL are at an increased risk of SPM, particularly NHL, Hodgkin lymphoma and AML. Older patients and men are at a particularly increased risk of SPM and may benefit from trials on cancer screening and prevention. Grant Acknowledgement: University of Nebraska Medical Center, College of Medicine, Physician-Scientist Training Program Grant 2015-2016 to Vijaya Bhatt.